Lubna N Chaudhary
Overview
Explore the profile of Lubna N Chaudhary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pierro M, Zhang A, Chaudhary L
JAMA Oncol
. 2023 Feb;
9(4):564-565.
PMID: 36795394
No abstract available.
12.
Chervoneva I, Peck A, Sun Y, Yi M, Udhane S, Langenheim J, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2100498.
PMID: 36652667
Purpose: T-cell-mediated cytotoxicity is suppressed when programmed cell death-1 (PD-1) is bound by PD-1 ligand-1 (PD-L1) or PD-L2. Although PD-1 inhibitors have been approved for triple-negative breast cancer, the lower...
13.
Sridhar N, Glisch C, Jawa Z, Chaudhary L, Kamaraju S, Burfeind J, et al.
J Cancer
. 2022 Jun;
13(8):2472-2476.
PMID: 35711833
Androgen receptor (AR) expression has emerged as a potential prognostic and predictive marker in patients with triple negative breast cancer (TNBC). We conducted a retrospective analysis to evaluate pathologic complete...
14.
Griffiths C, Connelly J, Chaudhary L
JAMA Oncol
. 2021 May;
7(8):1239-1240.
PMID: 34042938
No abstract available.
15.
16.
Kamaraju S, Fowler A, Weil E, Wisinski K, Truong T, Lehr M, et al.
Endocrinology
. 2021 Mar;
162(8).
PMID: 33735382
Although incurable, the prognosis for patients with metastatic breast cancer (MBC) has considerably improved with the approvals of multiple targeted and cytotoxic therapies. For hormone receptor-positive (HR+), ie, estrogen receptor...
17.
Chaudhary L
Semin Oncol
. 2020 Jun;
47(4):201-208.
PMID: 32507668
Triple negative breast cancer is the most aggressive kind of breast cancer with high risk of recurrences and poor outcomes. Systemic chemotherapy has significantly improved long term outcomes in early...
18.
Chaudhary L, Jawa Z, Hanif A, Szabo A, Kamaraju S, Cheng Y, et al.
WMJ
. 2018 Jul;
117(2):62-67.
PMID: 30048574
Background: Local recurrence is a major concern in patients diagnosed with ductal carcinoma in situ (DCIS). In invasive breast cancers, estrogen receptor (ER) (+)/progesterone receptor (PR) (-) subtype is considered...
19.
Chaudhary L, Hope Wilkinson K, Kong A
Surg Oncol Clin N Am
. 2017 Nov;
27(1):141-153.
PMID: 29132557
Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant...
20.
Chaudhary L, Jawa Z, Szabo A, Visotcky A, Chitambar C
Hematol Oncol Stem Cell Ther
. 2016 Jan;
9(2):48-54.
PMID: 26808222
Objective/background: Progesterone-receptor negativity (PR-) is predictive of adverse outcomes in estrogen receptor-positive (ER+) breast cancer. The Oncotype DX assay provides risk stratification for hormone receptor-positive (HR+) invasive breast cancer; however,...